Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML0609

Sigma-Aldrich

Teniposide

≥97% (HPLC)

Synonym(s):

4′-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin, Tenoposide, VM-26

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C32H32O13S
CAS Number:
29767-20-2
Molecular Weight:
656.65
EC Number:
249-831-2
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥97% (HPLC)

form

powder

optical activity

[α]/D -100 to -115°, c = 1 in chloroform/methanol (9:1)

color

white to beige

solubility

DMSO: 10 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

InChI

1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1

InChI key

NRUKOCRGYNPUPR-QBPJDGROSA-N

Looking for similar products? Visit Product Comparison Guide

Application

Teniposide has been used as a topoisomerase II inhibitor to study its effects on the flagellum length in Trypanosoma brucei. It has also been used as a chemotherapeutic agent to study its interactions with piperazine(B87).

Biochem/physiol Actions

Teniposide (VM-26) is a Topoisomerase II inhibitor with antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, inducing breaks in double stranded DNA and preventing repair.
Teniposide is a derivative of podophyllotoxin and has been studied to treat several cancers. It acts during the late S phase or the early G2 phase of the cell cycle.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H350

Hazard Classifications

Carc. 1B

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 4

1 of 4

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Sigma-Aldrich

Sigma-Aldrich

5.04314

Bortezomib

Irinotecan hydrochloride topoisomerase inhibitor

Sigma-Aldrich

I1406

Irinotecan hydrochloride

Doxorubicin hydrochloride 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicin hydrochloride

Mauro Pagani
The Medical clinics of North America, 94(4), 835-852 (2010-07-09)
The number of drugs used for the treatment of different types of cancers is constantly increasing and actually exceeds 100 distinct chemical formulations. The use of most cytotoxic agents is associated with potential hypersensitivity reactions, and the constant increase of
Suna He et al.
AAPS PharmSciTech, 13(3), 846-852 (2012-05-31)
In order to tackle the problems on low water solubility of teniposide, involvement of toxic surfactant in its injection, and the poor stability during infusion, a Cremophor-free teniposide self-microemulsified drug delivery system (TEN-SMEDDS) was prepared for the first time, characterized
Kaori Kadoyama et al.
Journal of experimental & clinical cancer research : CR, 30, 93-93 (2011-10-06)
Previously, adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) database were reviewed to confirm platinum agent-associated hypersensitivity reactions. The present study was performed to confirm whether the database could suggest the hypersensitivity reactions caused by
Michael J Joyce et al.
Journal of pediatric hematology/oncology, 35(1), 32-35 (2012-12-06)
Children with acute lymphocytic leukemia who fail to enter remission have a poor prognosis. In a previous study, 9 of 14 children with induction failure entered remission after teniposide (VM26) plus cytosine arabinoside (Ara-C). We attempted to confirm these results.
Baohong Wang et al.
Hematological oncology, 31(1), 29-33 (2012-04-11)
There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service